NEW YORK, April 17, 2015 /PRNewswire/ -- MabVax Therapeutics Inc. (OTCQB: MBVX) based out of SAN DIEGO, CA is on the run to develop vaccines and antibodies based products to target specific forms of cancer. MabVax has an exclusive license to develop their vaccines at Memorial Sloan-Kettering Cancer Center (MSKCC). They then generate the monoclonal antibody with patients that have been treated with these licensed vaccines. MabVax is one of very few companies in the industry using this technique.
MabVax has vaccines undergoing Phase I and II trials and is expecting to reach major milestones in 2016. The lead product on the antibody approach is the HuMab 5B1 and it is currently undergoing Phase I trials. It is expected to have triple purpose as it has shown potential to treat pancreatic and colon cancer, to diagnose pancreatic cancer and to be an antibody drug conjugate.
By company's estimations there is a potential market opportunity for the sarcoma vaccines ranging from $200 - $300 millions in annual sales and for the ovarian cancer vaccines the potential market is $200 - $400 millions once the vaccines complete all the required phases and can be commercialized. For the antibody HuMab 5B1 the company estimates broadly 96,000 new patients a year with metastatic pancreatic and colon cancer meaning an annual potential market of $1 billion.
A report including analysis of MabVax Therapeutics Inc. financials, market position and analyst opinions can be viewed by clicking the link below. There is no cost obligation to view the analyst brief.
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Juanca Gutierrez, CFA Candidate. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.